2. Signaling Pathways
  3. MAPK/ERK Pathway
  4. p38 MAPK
  5. p38 MAPK Inhibitor

p38 MAPK Inhibitor

p38 MAPK Isoform Comparison

p38 MAPK Inhibitors (433):

Cat. No. Product Name Effect Purity
  • HY-N15496
    Fusaproliferin
    		Inhibitor
    Fusaproliferin is a sesterterpene mycotoxin isolated from Fusarium solani. Fusaproliferin reverse Lipopolysaccharides (HY-D1056) stimulation and the NF-κB and MAPKs signaling pathways contribute to the anti-inflammatory process. Fusaproliferin exhibits affinity for the TLR4 protein with KD values of 28.6 μM. Fusaproliferin shows cytotoxicity against pancreatic cancer cell with rapid and sub-micromolar IC50.
  • HY-176228
    WEIZ-WX-04-008
    		Inhibitor
    WEIZ-WX-04-008 (Compound 1) is a covalent Lysine-targeting MKK7 inhibitor with IC50 of 738 nM.
  • HY-171275
    p38 MAP Kinase-IN-1
    		Inhibitor
    p38 MAP Kinase-IN-1 (Compound 4) is the inhibitor for p38, and can be used for inflammation and auto-immune responses related research.
  • HY-164530
    SKLB646
    		Inhibitor
    SKLB646 is an orally active multi-target kinase inhibitor. SKLB646 shows significant inhibitory effects on SRC and VEGFR2 with IC50 values ??of 0.002 μmol/L and 0.012 μmol/L, respectively. SKLB646 also shows significant inhibitory effects on B-Raf and C-Raf with IC50 values ??of 0.022 μmol/L and 0.019 μmol/L, respectively. SKLB646 inhibits the activation of the SRC signaling pathway and blocks the MAPK signaling pathway by inhibiting Raf kinase. In addition, SKLB646 can inhibit the proliferation, migration and invasion of human umbilical vein endothelial cells (HUVEC) to inhibit tumor-induced angiopoietic formation. SKLB646 shows significant anti-proliferative and anti-survival activities against triple-negative breast cancer (TNBC) cell lines.
  • HY-N0721R
    Neoandrographolide (Standard)
    		Inhibitor
    Neoandrographolide (Standard) is the analytical standard of Neoandrographolide. This product is intended for research and analytical applications. Neoandrographolide is a diterpenoid compound isolated from Andrographis paniculata. Neoandrographolide inhibits osteoclasts differentiation and bone resorption through inhibition of MAPK/NF-κB/PI3K/AKT/GSK3β/PPAR/CAMK signaling pathway. Neoandrographolide inhibits apoptosis in rat embryonic ventricular cardiomyocytes. Neoandrographolide inhibits iNOS and the generation of ROS, activates eNOS, exhibiting anti-inflammatory and hypolipidemic activity.
  • HY-169685
    p38 MAPK-IN-6
    		Inhibitor
    p38 MAPK-IN-6 (compound c47) is a p38 MAPK inhibitor. p38 MAPK-IN-6 shows 14% inhibition at 10 μM.
  • HY-100278
    AKP-001
    		Inhibitor
    AKP-001 is an inhibitor of p38 mitogen-activated protein kinase (p38 MAPK). AKP-001 can inhibit the production of inflammatory cytokines and can be used for research in rheumatoid arthritis and inflammatory bowel disease.
  • HY-10261BR
    (E/Z)-Afatinib (Standard)
    		Inhibitor
    (E/Z)-Afatinib (Standard) is the analytical standard of (E/Z)-Afatinib. This product is intended for research and analytical applications. (E/Z)-Afatinib ((E/Z)-BIBW 2992) is the mixture of (E)-Afatinib and (Z)-Afatinib. Afatinib (HY-10261) is an irreversible inhibitor of EGFR, by irreversibly binding to their ATP binding site to block activation of EGFR, HER2, HER4, and EGFRvIII. Afatinib used in co-administration with Temozolomide (HY-17364), potently targeting to EGFRvIII-cMet signaling in glioblastoma cells.
  • HY-10256R
    Adezmapimod (Standard)
    		Inhibitor
    Adezmapimod (Standard) is the analytical standard of Adezmapimod. This product is intended for research and analytical applications. Adezmapimod (SB 203580) is a selective and ATP-competitive p38 MAPK inhibitor with IC50s of 50 nM and 500 nM for SAPK2a/p38 and SAPK2b/p38β2, respectively. Adezmapimod inhibits LCK, GSK3β and PKBα with IC50s of 100-500-fold higher than that for SAPK2a/p38. Adezmapimod does not disrupt JNK activity and is an autophagy and mitophagy activator.
  • HY-168090
    Anti-osteoporosis agent-11
    		Inhibitor
    Anti-osteoporosis agent-11 (compound 3k) is an anti-osteoporosis compound targeting osteoclasts. Anti-osteoporosis agent-11 has the most significant inhibitory effect on osteoclast differentiation, with an IC50 value of 0.36 μM. In addition, Anti-osteoporosis agent-11 inhibits osteoclast formation, bone resorption, and the expression of osteoclast-specific genes by blocking rankl-induced mitogen-activated protein kinase (MAPK) and NF-κB signaling pathways.
  • HY-B1104R
    Indoprofen (Standard)
    		Inhibitor
    Indoprofen (Standard) is the analytical standard of Indoprofen. This product is intended for research and analytical applications. Indoprofen activates AKT-AMPK signaling pathway, inhibits NF-κB/MAPK signaling pathway. Indoprofen exhibits anti-inflammatory and immunomodulatory activities. Indoprofen is orally active.
  • HY-103167
    CGH2466 dihydrochloride
    		Inhibitor
    CGH 2466 dihydrochloride is an orally active adenosine A1, A2B and A3 receptor antagonist with the IC50 values of 19 nM, 21 nM, and 80 nM respectively. CGH 2466 dihydrochloride inhibits p38 MAPK (IC50 = 187~ 400 nM) and phosphodiesterase type 4D (IC50 = 22 nM). CGH 2466 dihydrochloride displays potent anti-inflammatory effects both in vitro and in vivo, and can be used for research on asthma and chronic obstructive pulmonary disease (COPD).
  • HY-17007S2
    Saquinavir-13C6
    		Inhibitor
    Saquinavir-13C6 (Ro 31-8959-13C6) is 13C labeled Saquinavir (HY-17007). Saquinavir (Ro 31-8959) is an orally active HIV protease inhibitor that can be used in the research of AIDS. Saquinavir also has anti-inflammatory activity and can induce apoptosis of human red blood cells.
  • HY-107744R
    Nalmefene (Standard)
    		Inhibitor
    Nalmefene (Standard) is the analytical standard of Nalmefene. This product is intended for research and analytical applications. Nalmefene is a long acting opioid (MOR and DOR antagonist), and a partial KOR agonist. Nalmefene is used for opioid overdose and alcohol dependence.
  • HY-N1190
    DL-Syringaresinol
    		Inhibitor
    DL-Syringaresinol ((±)-Syringaresinol), a lignin, inhibits UVA-induced upregulation of MMP-1 by suppressing MAPK/AP-1 signaling in human HaCaT keratinocytes and dermal fibroblasts (HDFs). DL-Syringaresinol has antiphotoaging properties against UVA-induced skin aging. DL-Syringaresinol exhibits weak antimycobacterial activity against Mycobacterium tuberculosis H37Rv.
  • HY-171296
    p38 Kinase inhibitor 8
    		Inhibitor
    p38 Kinase inhibitor 8 (Compound CCLXXVIII) is the orally active inhibitor for p38β and JNK2α2 with IC50s of 6.3 nM and 53.6 nM. p38 Kinase inhibitor 8 exhibits anti-inflammatory effect in rats collagen-induced arthritis models.
  • HY-10405R
    Pamapimod (Standard)
    		Inhibitor
    Pamapimod (Standard) is the analytical standard of Pamapimod. This product is intended for research and analytical applications. Pamapimod (Ro4402257) is a potent, selective and orally active p38 MAPK inhibitor with IC50s of 14 nM and 480 nM and Kis of 1.3 nM and 120 nM for p38α and p38β, respectively. Pamapimod has no activity against p38δ or p38γ isoforms. Pamapimod has the potential for rheumatoid arthritis and other autoimmune diseases treatment.
  • HY-N15272
    Artocarpesin
    		Inhibitor
    Artocarpesin is a flavonoid compound. Artocarpesin has inhibitory effects on methicillin-resistant Staphylococcus aureus (MRSA). Artocarpesin inhibits the production of NO, PGE2 and ROS by inhibiting COX-2 and iNOS expression, and plays an anti-inflammatory role. In addition, Artocarpesin inhibits platelet aggregation by inhibiting cyclic nucleotides and MAPKs, which can be used in the study of cardiovascular diseases.
  • HY-124284R
    Hexamethylene bisacetamide (Standard)
    		Inhibitor
    Hexamethylene bisacetamide (Standard) is the analytical standard of Hexamethylene bisacetamide. This product is intended for research and analytical applications. Hexamethylene bisacetamide (HMBA) is a differentiation inducer and selective bromine domain inhibitor that can differentiate across the blood-brain barrier. Hexamethylene bisacetamide can induce tumor cell differentiation and inhibit cell proliferation, showing antitumor activity. Hexamethylene bisacetamide induces apoptosis by Notch1, Bcl-2 and p53 signaling pathways. In addition, Hexamethylene bisacetamide improves the obesity phenotype of mice.
  • HY-100618R
    Hispidin (Standard)
    		Inhibitor
    Hispidin (Standard) is the analytical standard of Hispidin. This product is intended for research and analytical applications. Hispidin, a PKC inhibitor and a phenolic compound can be found in Phellinus linteus, has been shown to possess strong anti-oxidant, anti-cancer, anti-diabetic, and anti-dementia properties[1][2][3][4][5][6][7].